FiercePharma, by Angus Liu, Jan 29, 2019 Pfizer has launched China’s first pay-for-performance program in oncology with its blockbuster breast cancer drug Ibrance, China Daily reported. Under the new program, called Bo’ai Xin’an, Pfizer promises reimbursement of up to 33.5% of Ibrance costs if an enrolled patient’s disease progresses within four months. The U.S. pharma set […]
January 7, 2016 – By Matthew Driskill in FiercePharmaAsia The Chinese government is expected to announce a precision medicine initiative in March that is expected to be over $9 Billion over 15 years – far beyond the $215 million U.S. plan announced last year. With that funding, many research projects around genome sequencing and specifically […]
PharmaTimes on 17. November 2015 The National Institute for Health and Care Excellence has published final draft guidance rejecting the use of Kadcyla (trastuzumab-emtansine) for patients as the first and only targeted chemotherapy for secondary HER2-positive breast cancer, because of its high price tag – around £90,000 per course (list price). Full article at PharmaTimes: […]
PharmaTimes on 18. Nov. 2015 Merck Serono’s Erbitux and Amgen’s Vectibix cannot be used as first line therapies alongside chemotherapy for RAS wild-type metastatic colorectal cancer. While recognising their clinical effectiveness, the Institute’s Expert Review group concluded that even if they were provided for free they would still not be cost-effective, as the methodology used […]